| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin aspart |
| Brand | NovoRapid® FlexTouch ® |
| Indication | For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
| Assessment Process | |
| Rapid review commissioned | 22/07/2014 |
| Rapid review completed | 28/08/2014 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
